GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4

The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes

Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?

Lead sponsor

Tina Vilsboll

Assets

GLP-1 / incretin class catch-all / Liraglutide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c 7-11%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01455441

Org study ID60 - TrainIncretin

Timeline

Milestones

Study first posted2011-10-20estimated

Last update posted2015-05-29estimated

Study start2011-10 (month precision)

Primary completion2013-06actual (month precision)

Study completion2014-06actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed oral and written consent

•Diagnosed with type 2 diabetes according to the criteria of the WHO

•HbA1C: 7-11% (doing treatment with diet and/or metformin)

•Age >18 years

•BMI >25 kg/m2 <40 kg/m2

•Negative islet cell antibodies (ICA) and glutamate decarboxylase 65 (GAD- 65) autoantibodies

Exclusion criteria

•Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures.

•Subjects treated with sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, insulin or glitazones

•Ongoing abuse of alcohol or narcotics

•Impaired hepatic function (liver transaminases >2 times upper normal limit)

•Impaired renal function (se-creatinine >150μM and/or albuminuria)

•Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months

•Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)

•Anaemia

•Any condition that the investigators feels would interfere with trial participation

•Receiving any investigational drug within the last 3 months

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Heart failure

Cardiometabolic biomarkers

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Body weight

Time frame:16 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

HbA1c

Time frame:16 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Glycaemic control

Time frame:16 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Meal test

Time frame:16 weeks

Postprandial glucose

change from baseline, improvement

Heart failure

1 endpoint

Secondary/protocol endpoint

Maximal oxygen uptake (VO2peak)

Time frame:16 weeks

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Blood pressure

Time frame:16 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Myocardial echocardiography

Time frame:16 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.